Aurobindo Pharma reported INR982.1M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
Cipla INR 131.3M 9M Mar/2026
Divis Laboratories Ltd INR 60M 0 Mar/2026
Dr.Reddys Laboratories INR 1.06B 113M Mar/2026
Hindustan Unilever INR 760M 120M Mar/2026
Sun Pharmaceuticals INR 998.6M 250.6M Sep/2025
UPL INR 7.74B 210M Dec/2025